<code id='63CEA78047'></code><style id='63CEA78047'></style>
    • <acronym id='63CEA78047'></acronym>
      <center id='63CEA78047'><center id='63CEA78047'><tfoot id='63CEA78047'></tfoot></center><abbr id='63CEA78047'><dir id='63CEA78047'><tfoot id='63CEA78047'></tfoot><noframes id='63CEA78047'>

    • <optgroup id='63CEA78047'><strike id='63CEA78047'><sup id='63CEA78047'></sup></strike><code id='63CEA78047'></code></optgroup>
        1. <b id='63CEA78047'><label id='63CEA78047'><select id='63CEA78047'><dt id='63CEA78047'><span id='63CEA78047'></span></dt></select></label></b><u id='63CEA78047'></u>
          <i id='63CEA78047'><strike id='63CEA78047'><tt id='63CEA78047'><pre id='63CEA78047'></pre></tt></strike></i>

          hotspot

          hotspot

          author:comprehensive    Page View:6
          Vertex Pharmaceuticals Inc. building
          Craig F. Walker/The Boston Globe

          Vertex Pharmaceuticals said Friday that, over a year after receiving the company’s stem-cell therapy, two type 1 diabetes patients no longer need to take insulin injections and saw stark reductions in a biological marker of disease. 

          The results, presented at the American Diabetes Association conference in San Diego, bolstered experts’ hopes that the treatment could provide a functional cure for some patients. In 2021, Vertex announced dramatic results from the first man to receive the treatment, but researchers cautioned it was just one person, who had only been followed for 90 days.

          advertisement

          “The data look as good as they could be,” said Jeanne Loring, a stem cell expert and professor emeritus at Scripps Research not involved in the work, in an email.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Susan Tousi leaves Illumina to head cancer liquid biopsy startup
          Susan Tousi leaves Illumina to head cancer liquid biopsy startup

          SusanTousiisleavingIlluminatobecomeCEOofcancerliquid-biopsystartupDelfi.NasdaqDelfiDiagnostics,astar

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          Generative AI mines health records to identify patients’ social needs

          AdobeGenerativeAI’searliestapplicationsinmedicinehavelargelyfocusedoncuringnotpatients,buttheplagueo